糖尿病神经病变患者外周神经阻滞特征的前瞻性队列研究
这项前瞻性队列研究比较了合并糖尿病周围神经病变的2型糖尿病患者与无神经病变患者接受超声引导下腘窝坐骨神经阻滞的特征。结果显示,糖尿病神经病变组首次阿片类药物请求时间显著延长,感觉阻滞起效时间缩短59%,术后第1天静息疼痛评分更低。
要点
- 糖尿病神经病变患者腘窝坐骨神经阻滞后首次阿片请求时间中位数显著延长(1440 min vs 710 min)。
- 糖尿病神经病变患者感觉阻滞起效时间较对照组缩短59%(时间比0.41)。
- 糖尿病神经病变患者术后第1天静息疼痛评分中位数更低(0 vs 3)。
核心结论
- 合并糖尿病周围神经病变的2型糖尿病患者接受超声引导下腘窝坐骨神经阻滞后,感觉阻滞起效时间缩短,首次阿片类药物请求时间延长。
研究设计与样本
- 所有患者接受超声引导下腘窝坐骨神经阻滞,注射30 ml 1%利多卡因与0.5%布比卡因1:1混合液。
- 主要结局为阻滞后首次阿片类药物请求时间;次要结局包括感觉阻滞起效时间和术后第1天静息疼痛评分(NRS 0-10)。
- 采用加速失效时间回归模型分析。
主要发现
- 糖尿病周围神经病变组首次阿片请求时间中位数(IQR[范围])为1440(1140-1440[180-1440])min,对照组为710(420-1200[150-1440])min,p=0.0004。
- 糖尿病周围神经病变组时间比为1.57(95%CI 1.10-2.23,p<0.01)。
- 糖尿病周围神经病变组感觉阻滞起效时间缩短59%,中位时间比0.41(95%CI 0.28-0.59),p<0.0001。
- 术后第1天静息疼痛评分中位数(IQR[范围]):糖尿病周围神经病变组0(0-1[0-5]),对照组3(0-5[0-9]),p=0.001。
临床怎么用
- 对于合并糖尿病周围神经病变的2型糖尿病患者,行超声引导下腘窝坐骨神经阻滞时,应预期感觉阻滞起效更快、阻滞持续时间更长。
- 此类患者术后镇痛需求可能延迟,应据此调整术后疼痛评估和阿片类药物备用方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Animal data have demonstrated increased block duration after local anaesthetic injections in diabetic rat models. Whether the same is true in humans is currently undefined. We, therefore, undertook this prospective cohort study to test the hypothesis that type-2 diabetic patients suffering from diabetic peripheral neuropathy would have increased block duration after ultrasound-guided popliteal sciatic nerve block when compared with patients without neuropathy. Thirty-three type-2 diabetic patients with neuropathy and 23 non-diabetic control patients, scheduled for fore-foot surgery, were included prospectively. All patients received an ultrasound-guided popliteal sciatic nerve block with a 30 ml 1:1 mixture of lidocaine 1% and bupivacaine 0.5%. The primary outcome was time to first opioid request after block procedure. Secondary outcomes included the time to onset of sensory blockade, and pain score at rest on postoperative day 1 (numeric rating scale 0-10). These outcomes were analysed using an accelerated failure time regression model. Patients in the diabetic peripheral neuropathy group had significantly prolonged median (IQR [range]) time to first opioid request (diabetic peripheral neuropathy group 1440 (IQR 1140-1440 [180-1440]) min vs. control group 710 (IQR 420-1200 [150-1440] min, p = 0.0004). Diabetic peripheral neuropathy patients had a time ratio of 1.57 (95%CI 1.10-2.23, p < 0.01), experienced a 59% shorter time to onset of sensory blockade (median time ratio 0.41 (95%CI 0.28-0.59), p < 0.0001) and had lower median (IQR [range]) pain scores at rest on postoperative day 1 (diabetic peripheral neuropathy group 0 (IQR 0-1 [0-5]) vs. control group 3 (IQR 0-5 [0-9]), p = 0.001). In conclusion, after an ultrasound-guided popliteal sciatic nerve block, patients with diabetic peripheral neuropathy demonstrated reduced time to onset of sensory blockade, with increased time to first opioid request when compared with patients without neuropathy.
引用
- Baeriswyl M, Taffé P, Kirkham KR, et al. Comparison of peripheral nerve blockade characteristics between non-diabetic patients and patients suffering from diabetic neuropathy: a prospective cohort study. Anaesthesia. 2018. PMID: 29858510. doi:10.1111/anae.14347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。